Brief: Diamyd Medical Discontinues Diagnode-3 Following Evaluation Confirming Futility Initiates Strategic Review
10/04/2026 18:11
April 10 (Reuters) - DIAMYD MEDICAL DISCONTINUES DIAGNODE-3 FOLLOWING EVALUATION CONFIRMING FUTILITY; INITIATES STRATEGIC REVIEW DIAMYD MEDICAL AB - INITIATES ORDERLY WIND-DOWN OF DIAGNODE-3 TRIAL DIAMYD MEDICAL AB - COMPANY TO ADJUST STAFFING AND COSTS FOLLOWING TRIAL DISCONTINUATION DIAMYD MEDICAL AB - NO NEW SAFETY CONCERNS IDENTIFIED IN INTERIM ANALYSIS DIAMYD MEDICAL AB - INTERIM RESULTS MEET FUTILITY CRITERIA; TRIAL DISCONTINUED Source text: ID:nWkr3Sgw4m Further company coverage: [DMYDb.ST] ((Reuters.Briefs@thomsonreuters.com;))